Quickly supply alternative strategic theme areas vis-a-vis B2C mindshare. Objectively repurpose stand-alone synergy via user-centric architectures.
After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. The question is whether this rally marks a real recovery or just another short-lived bounce.
Read More
Lab-made technology with living tissue could guide future drug development, scientists say.
Read More
The U.S. Department of Health and Human Services, helmed by Health and Human Services Secretary Robert F. Kennedy Jr., has pulled funding and cancelled contracts for vaccine development projects involving mRNA technology.
Read More
Months into President Donald Trump’s second term, as his administration wages an unprecedented war on the country’s top universities and research institutions,
Read More
With the welcome mat withdrawn for promising researchers from around the world, America is at risk of losing its longstanding pre-eminence in the sciences.
Read More
It started as a crackdown on DEI. Now all types of research are being cancelled
Read More
The transaction would see Sanofi purchase all of Vigil’s outstanding shares for an upfront payment of $8 a share
Read More
NIAID’s Integrated Research Facility is one of the few federal facilities charged with studying Ebola. Tuesday afternoon, all of its work was put on indefinite pause by Robert F. Kennedy Jr.’s department.
Read More
Reducing federal support for research and development could cause long-run economic damage and reduce government revenue.
Read More